| Ethnicity and spirometric indices: hostage to tunnel vision? | Lancet Respiratory Medicine | 1 day | save |  |  |  |  |
| How sustainable are new treatment strategies for NSCLC? | Lancet Respiratory Medicine | 1 day | save | | | | |
| Post-traumatic stress in the intensive care unit | Lancet Respiratory Medicine | 2 days | save | | | | |
| Efforts to tackle air pollution should focus on accountability | Lancet Respiratory Medicine | 3 days | save | | | | |
| Effects of saline or albumin fluid bolus in resuscitation: evidence from re-analysis of the FEAST trial | Lancet Respiratory Medicine | 5 days | save | | | | |
| Adverse effects of bolus fluid resuscitation—short-term benefit but long-term harm | Lancet Respiratory Medicine | 5 days | save | | | | |
| Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia | Lancet Respiratory Medicine | 8 days | save | | | | |
| Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial | Lancet Respiratory Medicine | 9 days | save | | | | |
| Finding the missing millions affected by tuberculosis is one thing; treating them is another | Lancet Respiratory Medicine | 9 days | save | | | | |
| Cardiopulmonary haemodynamics in portopulmonary hypertension | Lancet Respiratory Medicine | 9 days | save | | | | |
| Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial | Lancet Respiratory Medicine | 9 days | save | | | | |
| Inhaled hypertonic saline for 3–6-year-olds with cystic fibrosis | Lancet Respiratory Medicine | 9 days | save | | | | |
| Managing asthma in pregnancy: effects on future child health | Lancet Respiratory Medicine | 9 days | save | | | | |
| Tuberculosis: a much-needed focus on transmission | Lancet Respiratory Medicine | 18 days | save | | | | |
| Machine learning molecular classification in IPF: UIP or not UIP, that is the question | Lancet Respiratory Medicine | 25 days | save | | | | |
| Aligning use of intensive care with patient values in the USA: past, present, and future | Lancet Respiratory Medicine | 25 days | save | | | | |
| Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study | Lancet Respiratory Medicine | 25 days | save | | | | |
| A framework for improving post-critical illness recovery through primary care | Lancet Respiratory Medicine | 25 days | save | | | | |
| Why is it so hard to stop doing things that are unwanted, non-beneficial, or unsustainable? | Lancet Respiratory Medicine | 25 days | save | | | | |
| Understanding irresponsible use of intensive care unit resources in the USA | Lancet Respiratory Medicine | 25 days | save | | | | |
| Eosinophil-guided treatment of COPD exacerbations: unfinished business | Lancet Respiratory Medicine | 25 days | save | | | | |
| Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial | Lancet Respiratory Medicine | 25 days | save | | | | |
| Pragmatic methods to avoid intensive care unit admission when it does not align with patient and family goals | Lancet Respiratory Medicine | 25 days | save | | | | |
| Intensive care unit provision at the end of life: miles travelled, miles to go | Lancet Respiratory Medicine | 25 days | save | | | | |
| Human pentraxin 2 protein treatment for IPF | Lancet Respiratory Medicine | 25 days | save | | | | |
| Beyond silicosis, is the world failing on silica hazards? | Lancet Respiratory Medicine | 29 days | save | | | | |
| Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial | Lancet Respiratory Medicine | 31 days | save | | | | |
| The future of mesothelioma treatment: time to shift gear | Lancet Respiratory Medicine | 31 days | save | | | | |
| Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial | Lancet Respiratory Medicine | 37 days | save | | | | |
| New asthma treatment recommendations | Lancet Respiratory Medicine | 37 days | save | | | | |
| Whole-body MRI for lung cancer staging: a step in the right direction | Lancet Respiratory Medicine | 37 days | save | | | | |
| Wearable technology for air pollution | Lancet Respiratory Medicine | 37 days | save | | | | |
| Expiratory airflow in late adolescence and early adulthood in individuals born very preterm or with very low birthweight compared with controls born at term or with normal birthweight: a meta-analysis of individual participant data | Lancet Respiratory Medicine | 38 days | save | | | | |
| Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies | Lancet Respiratory Medicine | 38 days | save | | | | |
| Lung function deficits of adults born very preterm and with very low birthweight | Lancet Respiratory Medicine | 38 days | save | | | | |
| Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol | Lancet Respiratory Medicine | 39 days | save | | | | |
| Asthma heterogeneity: the increasing genetic evidence | Lancet Respiratory Medicine | 49 days | save | | | | |
| Peru's commendable strides towards tuberculosis elimination | Lancet Respiratory Medicine | 49 days | save | | | | |
| Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies | Lancet Respiratory Medicine | 49 days | save | | | | |
| Normal polysomnography parameters in healthy adults: a systematic review and meta-analysis | Lancet Respiratory Medicine | 58 days | save | | | | |
| New evidence on sleep ontogeny in adults | Lancet Respiratory Medicine | 58 days | save | | | | |
| Tuberculosis in diabetes: insidious and neglected | Lancet Respiratory Medicine | 60 days | save | | | | |
| An ethics framework and practical guidance for post-trial access to an RSV maternal vaccine | Lancet Respiratory Medicine | 60 days | save | | | | |
| Advances in chronic obstructive pulmonary disease genetics: building the picture one piece at a time | Lancet Respiratory Medicine | 61 days | save | | | | |
| Exploring the optimal use of alectinib | Lancet Respiratory Medicine | 61 days | save | | | | |
| Early-onset emphysema in a large French-Canadian family: a genetic investigation | Lancet Respiratory Medicine | 61 days | save | | | | |
| The gender gap in critical care task force participation | Lancet Respiratory Medicine | 61 days | save | | | | |
| Precision medicine in obstructive sleep apnoea | Lancet Respiratory Medicine | 64 days | save | | | | |
| Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study | Lancet Respiratory Medicine | 66 days | save | | | | |
| Functional effects of the microbiota in chronic respiratory disease | Lancet Respiratory Medicine | 68 days | save | | | | |
| | 
report | next » |
| |
